by April Breyer Menon | May 20, 2021
Venable’s Ha Kung Wong participated in a panel discussion of antitrust issues relating to IP litigations in the pharmaceutical industry. This is the second webinar in a three-part series, discussing patent infringement lawsuits from the perspectives of...
by April Breyer Menon | May 5, 2021
Venable’s Ha Kung Wong, along with Daisy R. Muzzio, Shane Brunner, Joshua Resiburg, Jeffrey Lewis, and Neill Clark, discusses antitrust issues relating to IP litigations in the pharmaceutical industry. This is the first webinar in a three-part series,...
by April Breyer Menon | Apr 26, 2021
Two bipartisan bills, the Advancing Education on Biosimilars Act and the Ensuring Innovation Act, were signed into law by President Biden on April 23, 2021. According to U.S. Senator Bill Cassidy, MD (R-LA) who introduced the bills, they “both work to lower the price...
by April Breyer Menon | Apr 26, 2021
On April 23, 2021, Boehringer Ingelheim announced results from the VOLTIRE-X Phase III randomized study that evaluated switching patients with moderate-to-severe chronic plaque psoriasis between reference product Humira® (adalimumab) and biosimilar Cyltezo®...
by April Breyer Menon | Mar 2, 2021
On March 1, 2021, the Supreme Court heard oral argument in United States v. Arthrex, No. 19-1434, a case that will address whether administrative patent judges (APJs), who preside over inter partes reviews (IPRs) at the United States Patent and Trademark Office...
by April Breyer Menon | Feb 8, 2021
Venable Fizpatrick partner Ha Kung Wong spoke with Bloomberg Law for an article discussing the possible reasons for the recent decline in inter partes review (IPR) challenges to patents listed in the FDA’s Orange Book. The article by Bloomberg Law can be viewed...